Balanced news tone
News Sentiment
600276 sentiment intelligence
Jiangsu Hengrui Pharmaceuticals Co.,Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-4.6% over one week, +9.9% over four weeks, trend inactive, and near fair-value range.
Jiangsu Hengrui Pharmaceuticals' Contrast Agent Added to China's Essential Medicines List
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Jiangsu Hengrui Pharmaceuticals' Contrast Agent Added to China's Essential Medicines List
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 02:16
- Source
- Moomoo
Price to sales forward of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A – SSE:600276
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 13:33
- Source
- TradingView
Jiangsu Hengrui Pharmaceuticals stock (CNE0000014X5): Bristol Myers $15.2B deal sparks rally
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 May 2026 07:00
- Source
- Ad-hoc-news.de
Jiangsu Hengrui Pharmaceuticals stock (CNE0000014X5): Shares surge 13% on $15.2B BMS deal
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 12 May 2026 07:00
- Source
- Ad-hoc-news.de
China's Hengrui, Bristol Myers Squibb sign collaboration, licensing deals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 07:00
- Source
- Reuters
Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 11 May 2026 07:00
- Source
- Bloomberg.com
Can a Chinese drugmaker become a big pharma company? Hengrui is testing the waters
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jan 2026 08:00
- Source
- Endpoints News
Citigroup's long position in H shares of Jiangsu Hengrui Pharmaceuticals increases to 5.21% on Jan 14 - HKEX
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 20 Jan 2026 08:00
- Source
- marketscreener.com
Jiangsu Hengrui Pharmaceuticals Appoints New Senior Vice President
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Dec 2025 08:00
- Source
- The Globe and Mail
China’s Hengrui gets boost from fifth drug-licensing deal of year
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 25 Sep 2025 07:00
- Source
- South China Morning Post
Braveheart licenses Hengrui's heart drug HRS-1893 in $1B deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 05 Sep 2025 07:00
- Source
- BioWorld News
China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 05 Sep 2025 07:00
- Source
- South China Morning Post
Fierce Pharma Asia—GSK's massive Hengrui deal; Takeda's revenue drop; Celltrion's major US plant buy
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 01 Aug 2025 07:00
- Source
- Fierce Pharma
Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 28 Jul 2025 07:00
- Source
- Bloomberg.com
GSK, China's Jiangsu Hengrui strike $500 million drug-development deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 28 Jul 2025 07:00
- Source
- Reuters
GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jul 2025 07:00
- Source
- South China Morning Post
Jiangsu Hengrui jumps 25% in solid Hong Kong trading debut
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 May 2025 07:00
- Source
- South China Morning Post
Top Chinese Drugmaker Hengrui Set to Begin Hong Kong Trading
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 May 2025 07:00
- Source
- Bloomberg.com
China's Jiangsu Hengrui to raise $1.27 billion in Hong Kong listing
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 21 May 2025 07:00
- Source
- Reuters
China pharma migration: Hengrui greenlighted for Hong Kong IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2025 07:00
- Source
- BioWorld News
Jiangsu Hengrui, a preferred China partner for U.S. biotech, hints at more deals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jan 2025 08:00
- Source
- STAT
Hengrui Pharmaceutical (600276.SH): SHR-2173 injection obtained drug clinical trial approval notice
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 14 May 2024 07:00
- Source
- Moomoo